{"document_type": "article", "byline": {"person": [{"role": "reported", "firstname": "Robert", "organization": "", "rank": 1, "lastname": "CYRAN"}], "original": "By ROBERT CYRAN"}, "news_desk": "Business", "slideshow_credits": null, "abstract": null, "multimedia": [{"type": "image", "url": "images/2016/02/29/business/29valeant-web/29valeant-web-thumbWide.jpg", "legacy": {"wide": "images/2016/02/29/business/29valeant-web/29valeant-web-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "width": 190, "subtype": "wide", "height": 126}, {"type": "image", "url": "images/2016/02/29/business/29valeant-web/29valeant-web-articleLarge.jpg", "legacy": {"xlarge": "images/2016/02/29/business/29valeant-web/29valeant-web-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "395"}, "width": 600, "subtype": "xlarge", "height": 395}, {"type": "image", "url": "images/2016/02/29/business/29valeant-web/29valeant-web-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/02/29/business/29valeant-web/29valeant-web-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "width": 75, "subtype": "thumbnail", "height": 75}], "headline": {"kicker": "Breakingviews", "content_kicker": "Breakingviews", "main": "Valeant Chief Returns to a Difficult To-Do List"}, "print_page": null, "keywords": [{"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Valeant Pharmaceuticals International Inc", "is_major": "N", "rank": "2", "name": "organizations"}, {"value": "Actavis PLC", "is_major": "N", "rank": "3", "name": "organizations"}, {"value": "Salix Pharmaceuticals Ltd", "is_major": "N", "rank": "4", "name": "organizations"}, {"value": "Pearson, John Michael (1959- )", "is_major": "N", "rank": "5", "name": "persons"}], "snippet": "Even if the drug maker\u2019s delayed 2015 earnings are published soon, J. Michael Pearson\u2019s room for maneuvering is shrinking.", "source": "The New York Times", "lead_paragraph": "Even if the drug maker\u2019s delayed 2015 earnings are published soon, J. Michael Pearson\u2019s room for maneuvering is shrinking.", "word_count": "371", "pub_date": "2016-03-01T00:00:00Z", "subsection_name": "DealBook", "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/03/01/business/dealbook/valeant-chief-returns-to-a-difficult-to-do-list.html", "_id": "56d4bb2c38f0d811294b8142"}